Dr. Solomon talks PXT3003 Taking On Charcot Marie-Tooth Disease
Release Date: 01/13/2021
The Media's Viral Lie about Ivermectin Overdoses & Horse Medicine: Dr. Kory Responds | Interview
trialsitenews's podcast
In the last few weeks, the mainstream media ran with stories about Ivermectin, most noticeably referring to it as "horse medicine" or "horse dewormer" while, for some reason, leaving out the fact that Ivermectin is a WHO essential medicine for HUMANS.
info_outline
Kelly McKee from Medidata talks transforming the patient clinical trial experience
trialsitenews's podcast
An interview with Kelly McKee from Medidata on transforming the patient clinical trial experience.
info_outline
CATalyst | Indian Bar Association Serve Legal Notice on WHO's chief scientist Dr. Soumya Swaminathan
trialsitenews's podcast
info_outline
Ralph Lorigo Talks NY Court Rulings Over Ivermectin Use In Covid-19 Treatment | Interview
trialsitenews's podcast
We sit down with Ralph Lorigo, of the Law Office of Ralph C. Lorigo to discuss NY court cases regarding Ivermectin and Covid-19.
info_outline
Ralph Lorigo Talks NY Court Rulings Over Ivermectin Use In Covid-19 Treatment | Interview
trialsitenews's podcast
We sit down with Ralph Lorigo, of the Law Office of Ralph C. Lorigo to discuss NY court cases regarding Ivermectin and Covid-19.
info_outline
Shabnam Palesa Mohamed, discusses state of Ivermectin in South Africa | Podcast
trialsitenews's podcast
Shabnam Palesa Mohamed: Activist. journalist, mediator (LLB). Founder of SAHARI and THJ CEO, discusses state of Ivermectin in South Africa. We discuss the twists and turns of the legality issues of the drug, to a campaign to bring awareness through-out the country and beyond.
info_outline
Dr. Kedar discusses Covid-19 impact on bringing research to rural communities
trialsitenews's podcast
We talk with Dr. Kedar about rural research initiatives and the impact Covid-19 has had in bringing advanced research to them. Dr. Kedar specializes in autoimmune diseases that effect the musculoskeletal system, such as rheumatism, arthritis, and other disorders of the joints, muscles and ligaments.
info_outline
Melanie Rice: Patient Suffering from MS discusses her experience with the disease
trialsitenews's podcast
Melanie Rice who is suffering from Multiple Sclerosis. She was diagnosed Sept 20 2019 at the Mayo Clinic in Jacksonville Florida. Since then she has uncovered an entire community, or more appropriately, a family of thousands of people struggling with this autoimmune disease. She has become an advocate for MS patients, and so we have brought her on to talk with us about her illness.
info_outline
Sam Searcy Talks Accelerating The Clinical Trials Process With Cloud-Based Service Providers
trialsitenews's podcast
We sit down with Sam Searcy to talk about his Company Clinistart, and innovative cloud-based service providers designed to accelerate clinical trial site activation and study start up. The goal: accelerate each step of the clinical trials process to accelerate the availability of medicines sooner for patients.
info_outline
Dr. John Boockvar Of Lenox Hill Hospital Talks New Surgical Technique To Treat Glioblastoma
trialsitenews's podcast
We sit down for an interview with Dr. John Boockvar, vice chair of neurosurgery at Lenox Hill Hospital, who started a first-in-human clinical research study involving a new surgical technique to treat glioblastoma multiforme (GBM) - the most aggressive form of brain cancer.
info_outlineDr. David Horn Solomon, CEO of Pharnext discusses PXT3003 which is currently focused on the treatment of Charcot Marie-Tooth (CMT) disease Type 1A.
Charcot-Marie-Tooth is a degenerative nerve disease that usually appears in adolescence or early adulthood. CMT affects the Peripheral Nervous System. It is a progressive nerve disease. Nerves weaken over time, causing progressive disability starting in the toes and fingers and working toward the center of the body.
You can visit Pharnext by clicking on this link: https://pharnext.com/
About:
Dr. Solomon is a leader in the life sciences industry with a 30+ year track record. Prior to joining Pharnext, David served as the CEO of Silence Therapeutics (NASDAQ:SLN), Akari Therapeutics (NASDAQ:AKRI), Bionor Pharma (OSLO:BIONOR), and Zealand Pharma (NASDAQ:ZEAL) guiding Zealand through approval of Adlixin for Type II Diabetes. He was Managing Partner at Sund Capital in Denmark and also headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. A former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo, and Promosome, David is currently Chairman of the Board for Advicenne Pharma (PARIS: ADV) and Rexgenero in London. David was earlier a Professor of Pharmacology and Neurology at Columbia University’s College of Physicians and Surgeons in New York City.